In this paper, we report the preparation of LbL-nanoSraf (100-300 nm) comprising of layer-by-layer (LbL) assembled polyelectrolytes dextran-sulfate/poly-L-arginine, with a multikinase inhibitor sorafenib (Sraf) encapsulated calcium carbonate (CaCO3) nanoparticles for oral cancer therapy in vitro. The zeta potential of LbL-nanoSraf exhibited a negative charge of the polyanionic dextran sulfate, which alternated with a positive charge of polycationic poly-L-arginine indicating a successful LbL assembly of the two polyelectrolyte bilayers on the CaCO3 nanoparticles. The LbL-nanoSraf exhibited an encapsulation efficiency of 61 +/- 4%. The LbL-nanoSraf was characterized using field-emission gun scanning electron microscopy, Xray powder diffracti...
Shaomei Yang,1 Bo Zhang,1 Xiaowei Gong,2 Tianqi Wang,1 Yongjun Liu,1 Na Zhang1 1Department of Pharm...
Yao Yao, Zhihui Su, Yanchao Liang, Na Zhang School of Pharmaceutical Sciences, Shandong University,...
Abstract Although the application of sorafenib, a small inhibitor of tyrosine protein kinases, to ca...
Hepatocellular carcinoma is one of the most common cancers in adults and develops due to activation ...
Hepatocellular carcinoma is one of the most common cancers in adults and develops due to activation ...
Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib w...
Sorafenib, a molecular targeted multi-kinase inhibitor, has received considerable interests in recen...
Sorafenib is an anticancer drug approved by the Food and Drug Administration for the treatment of he...
Sorafenib is an anticancer drug approved by the Food and Drug Administration for the treatment of he...
<p>Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe...
In the present study, we select the Sylysia 350 (Sylysia) as mesoporous material, distearoylphosphat...
Sorafenib is an anticancer drug approved by the Food and Drug Administration for the treatment of he...
Globally, one in six deaths is reported due to cancer suggesting the critical need for development o...
Abstract In addition to early detection, early diagnosis, and early surgery, it is of great signific...
In this paper, we describe the preparation of polymeric nanoparticles (NPs) loaded with sorafenib fo...
Shaomei Yang,1 Bo Zhang,1 Xiaowei Gong,2 Tianqi Wang,1 Yongjun Liu,1 Na Zhang1 1Department of Pharm...
Yao Yao, Zhihui Su, Yanchao Liang, Na Zhang School of Pharmaceutical Sciences, Shandong University,...
Abstract Although the application of sorafenib, a small inhibitor of tyrosine protein kinases, to ca...
Hepatocellular carcinoma is one of the most common cancers in adults and develops due to activation ...
Hepatocellular carcinoma is one of the most common cancers in adults and develops due to activation ...
Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib w...
Sorafenib, a molecular targeted multi-kinase inhibitor, has received considerable interests in recen...
Sorafenib is an anticancer drug approved by the Food and Drug Administration for the treatment of he...
Sorafenib is an anticancer drug approved by the Food and Drug Administration for the treatment of he...
<p>Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and has fewer severe...
In the present study, we select the Sylysia 350 (Sylysia) as mesoporous material, distearoylphosphat...
Sorafenib is an anticancer drug approved by the Food and Drug Administration for the treatment of he...
Globally, one in six deaths is reported due to cancer suggesting the critical need for development o...
Abstract In addition to early detection, early diagnosis, and early surgery, it is of great signific...
In this paper, we describe the preparation of polymeric nanoparticles (NPs) loaded with sorafenib fo...
Shaomei Yang,1 Bo Zhang,1 Xiaowei Gong,2 Tianqi Wang,1 Yongjun Liu,1 Na Zhang1 1Department of Pharm...
Yao Yao, Zhihui Su, Yanchao Liang, Na Zhang School of Pharmaceutical Sciences, Shandong University,...
Abstract Although the application of sorafenib, a small inhibitor of tyrosine protein kinases, to ca...